These findings, alongside a broader body of evidence implicating inflammation in cardiovascular disease, have provided the rationale for ongoing Phase III clinical trials targeting IL‐6 signaling in atherosclerosis (ClinicalTrials.gov ID NCT05021835) [24, 25]. Here, IL6 is linked to cardiovascular disorder.